ArticleJTO clinical and research reports2022
Clinicopathologic Characteristics and Outcomes for Patients With
Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 9 citations in OpenAlex.
- SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.Translational oncology · 2026Article
- Targeted therapeutic strategies forTranslational lung cancer research · 2026Review
- Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape.Frontiers in oncology · 2026Review
- Therapeutic inhibition of RAS in non-small cell lung cancer.Frontiers in oncology · 2026Review
- Clinical and genomic characterization of KRAS G13X non-small cell lung carcinoma.Frontiers in oncology · 2026Article
- Article
- Immune checkpoint inhibitors have limited efficacy inTranslational lung cancer research · 2025Article
- TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Cancer research · 2025Article
- Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Cancer gene therapy · 2024Review
- A Critical Review of the Impact ofJournal of personalized medicine · 2024Review
- Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.Annals of surgical oncology · 2024Article
- Evaluation of SNaPshot and Sanger sequencing for the detection ofEcancermedicalscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Co-occurring mutations in Methods: This was a retrospective single-institution study. Patients with NSCLC and Results: A total of 107 patients with Conclusions: Co-occurring mutations were common in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.